The DOI matches its Crossref record; 64 of the 66 references it cites were found in a registry or an index.
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
Abstract
To formally establish the risk of lupus anticoagulants and anticardiolipin antibodies for arterial and venous thrombosis, we ran a MEDLINE search of the literature from 1988 to 2000. Studies were selected for their case-control (11), prospective (9), cross-sectional (3), and ambispective (2) design. They provided or enabled us to calculate the odds ratio with 95% confidence interval (CI) of lupus anticoagulants and/or anticardiolipin antibodies for thrombosis in 4184 patients and 3151 controls. Studies were grouped according to the antibody investigated. Five studies compared lupus anticoagulants with anticardiolipin antibodies: the odds ratio with 95% CI of lupus anticoagulants for thrombosis was always significant. None of them found anticardiolipin antibodies were associated with thrombosis. Four studies analyzed only lupus anticoagulants: the odds ratio with 95% CI was always significant. The risk of lupus anticoagulants was independent of the site and type of thrombosis, the presence of systemic lupus erythematosus, and the coagulation tests employed to detect them. Sixteen studies served to assess 28 associations between anticardiolipin antibodies and thrombosis: the odds ratio with 95% CI was significant in 15 cases. Anticardiolipin titer correlated with the odds ratio of thrombosis. In conclusion, the detection of lupus anticoagulants and, possibly, of immunoglobulin G (IgG) anticardiolipin antibodies at medium or high titers helps to identify patients at risk for thrombosis. However, to take full advantage of the conclusions provided by the available evidence, there is an urgent need to harmonize investigational methods.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results confirm and validate several previous reports that have implicated these antibodies in the pathogenesis of APS [9, 10, 12, 13, 29, 30], but they also add to the growing body of evidence that shows inconsistent associations between aPL-associated autoantibodies and anamnestic thrombotic risk [3, 16].”
From Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant (2017) · cites this paper as [29]
In the citing paper
“It is now clear that LA positivity is associated with TEs.22”
From Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study (2011) · cites this paper as [22]
In the citing paper
“It is well known that LA positivity is more strongly associated with both arterial and venous thrombosis than either aCL or anti-β2-glycoprotein I antibodies [8, 9].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [9]
In the citing paper
“Large studies found that IgM aCL and IgM anti-β2-glycoprotein I are not associated with thrombotic events [9–13].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [9]
In the citing paper
“Similarly, in a systematic review, aCL IgM was not predictive for thrombosis [9].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [9]
In the citing paper
“In most studies, it has been shown that in SLE, LA is the main predictor of thrombosis [9, 27–29].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [9]
In the citing paper
“Patients with persistent aPL with or without APS are at increased risk of future thrombotic events, LA positivity having the strongest association with these events.3”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [3]
In the citing paper
“Patients with persistent aPL with or without APS are at increased risk of future thrombotic events, LA positivity having the strongest association with these events.3”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [3]
In the citing paper
“Additional antibodies, most notably anticardiolipin antibodies (aCL) and anti–glycoprotein-I antibodies (aβ2GPI), were later identified and associated with thrombosis and recurrent spontaneous abortions.2-4”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [3]
In the citing paper
“Notably, most prior efforts to risk-stratify patients for future thrombotic events have used the patients’ aPL status from the first measurement or early in the observation period and have not analyzed changes over time.3,7,8”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [3]
In the citing paper
“This contention is supported by meta-analyses showing that the presence of aCL and ab2GPI alone are poorly associated with thromboembolic events [6,7].”
From Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome (2010) · cites this paper as [6]
In the citing paper
“Although a positive LAC is considered to be a strong risk factor for thrombosis in APS, 10,11”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [10]
Citations
Cites
McNeil, H. P., Simpson, R. J., Chesterman, C. N., & Krilis, S. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4120 · Cited by 1,595
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
Galli, M., Barbui, T., Comfurius, P., Maassen, C., Hemker, H. C., Zwaal, R. F. A., Bevers, E. M., Baets, M. H. D., & Vriesman, P. J. C. V. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)91374-j · Cited by 1,266
Self-citationBrandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
The “Primary” Antiphospholipid Syndrome
Asherson, R. A., Khamashta, M. A., Ordi, J., Derksen, R. H. W. M., Machin, S. J., Barquinero, J., OUTT, H. H., Harris, E. N., Vilardell, M., & Hughes, G. R. V. (1989) · Medicine · doi:10.1097/00005792-198911000-00004 · Cited by 963
The "primary" antiphospholipid syndrome: major clinical and serological features.
Asherson, R. A., Khamashta, M. A., Ordi‐Ros, J., Derksen, R. H. W. M., Machin, S. J., Barquinero, J., OUTT, H. H., Harris, E. N., Vilardell, M., & Hughes, G. R. V. (1989) · PubMed · Cited by 892
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
Alarcón-Segovia, D., Delezé, M., Oria, C. V., Sánchez‐Guerrero, J., Gómez-Pacheco, L., Cabiedes, J., Fernández, L. A. N., & de León, S. P. (1989) · Medicine · doi:10.1097/00005792-198911000-00003 · Cited by 635
Research works printed but not linked: 2
- Finazzi, 1989, Relative risk of recurrent abortion and thrombosis in young subjects with antiphospholipid antibodies estimated by case-control studies [abstract]., Postgrad Med J., 65, 697
- Barbui, 1989, A case-control estimate of the relative risk of cerebral ischaemic disease in young subjects with antiphospholipid antibodies [abstract]., Thromb Haemost., 62, 584
Cited by
Sorted by citations
Items 801–900 of 966
Saadalla, A. M., Chen, D., Stuart, M., Pruthi, R. K., Heikal, N., Snyder, M. R., Ashrani, A. A., & Seheult, J. N. (2024) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14251 · Cited by 1
“14,16,17 This study did not show a significant difference in the prevalence of TE events between the high and low DRVVT LAC titer groups.”
BackgroundElucidating the Neuropsychiatric Phenomena of Antiphospholipid Syndrome in a 31-Year-Old Female
Jamal, F., Kumar, R., & Hakobyan, N. (2024) · Cureus · doi:10.7759/cureus.64856 · Cited by 1
“APS is characterized by antibodies that do not directly interact with phospholipids but instead bind to plasma proteins situated on anionic surfaces, rendering the term APS somewhat misleading [4].”
BackgroundLupus anticoagulant, thrombosis, and death
Küçükkaya, R. D. (2015) · Blood · doi:10.1182/blood-2015-04-638320 · Cited by 1
Prevalencia de anticuerpos antifosfolípidos en pacientes con conectivopatías
Ruiz-Franco, O., Guerrero-Vásquez, M. E., Montenegro-Verástegui, C., et al. (2013) · Anales de la Facultad de Medicina · doi:10.15381/anales.v72i3.1066 · Cited by 1
Thrombophilie et infarctus du myocarde
Bouaziz, L., Slama, A. B. H., & Mahjoub, T. (2007) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/j.immbio.2007.07.004 · Cited by 1
Laboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome
Žigon, P., Mijovski, M. B., Frank‐Bertoncelj, M., Ambrožič, A., Tomšič, M., Hočevar, A., Božič, B., Šemrl, S. S., Kveder, T., & Čučnik, S. (2015) · InTech eBooks · doi:10.5772/61551 · Cited by 1
“6% despite the use of anticoagulants and/or salicylates [3, 4].”
BackgroundRare specific causes of stroke
Beck, A., Gölitz, P., & Schellinger, P. D. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9780511659096.022 · Cited by 1
Hematologic Disorders and Stroke
Bushnell, C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29544-4.00042-6 · Cited by 1
Maghraby, A. A. E., Kotb, H., Mokbel, A. N., et al. (2016) · Kasr Al Ainy Medical Journal · doi:10.4103/1687-4625.182554 · Cited by 1
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)
Barbhaiya, M., ANDRADE, D. C. O. D., Bertolaccini, M. L., et al. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_14 · Cited by 1
Tratamiento anticoagulante durante el embarazo
Chauleur, C., & Barjat, T. R. (2017) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(17)85966-x · Cited by 1
Has lupus anticoagulant testing had its day?
Fujieda, Y., & Atsumi, T. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0218-6 · Cited by 1
Diagnostic biologique du syndrome des antiphospholipides
Desage, S., & Dargaud, Y. G. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30096-4 · Cited by 1
Practice and performance of lupus anticoagulant tests: A single centre experience.
Za, K. T., Jayaranee, S., & Shanmugam, H. (2020) · PubMed · Cited by 1
Keikhaei, B., Saadati, N., Mahmoudian‐Sani, M., et al. (2021) · Clinical Rheumatology · doi:10.1007/s10067-020-05559-6 · Cited by 1
“phosphatidylserine, thereby creating a hypercoagulable state on the surface of the placenta, which can lead to thrombosis and miscarriage [6, 7].”
BackgroundYayla, M. E., Yüksel, M., EROĞLU, D. Ş., Torğutalp, M., Sezer, S., Dinçer, A. B. K., Gülöksüz, E. G. A., Yüksel, M. L., Ateş, A., Turgay, M., et al. (2021) · Journal of Ankara University Faculty of Medicine · doi:10.4274/atfm.galenos.2020.18189 · Cited by 1
Association of Lupus Anticoagulant with Brain Atrophy in Gulf War Illness (GWI)
James, L. M., Christova, P. S., Johnson, R., Engdahl, B. E., Lewis, S. M., Carpenter, A. F., & Georgopoulos, A. P. (2021) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2021/2.1215 · Cited by 1
“In addition to the brain effects observed here and elsewhere 16–21 , LAC is a risk factor for prothrombotic events 30 and myocardial infarction 31 , both of which occur at significantly higher rates in male Gulf War veterans compared to the general population 32 .”
López‐Candales, A., & Vallurupalli, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-78255-9_14 · Cited by 1
Antibodies and diagnostic tests in antiphosholipid syndrome
Chighizola, C. B., Borghi, M. O., & Meroni, P. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00059-3 · Cited by 2
Shrateh, O. N., Jobran, A. W. M., & Amoori, A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000556 · Cited by 1
“Positive LA test compared with aPL enzyme-linked immunosorbent assay tests([10]), moderate to high aCL or a2GPI IgG/IgM titer (40 U or 99th percentile) compared with lower titers, and IgG or IgM isotype compared with IgA isotype([1]), and triple aPL (LA, aCL, and aβ2GPI) positivity (compared with single or dual aPL te…”
ResultManifestations cliniques et biologiques Diagnostic du lupus érythémateux
Meyer, O. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-71447-4.50009-x · Cited by 1
Preparing the pediatric dialysis patient for transplantation
Sarwal, M., & Salvatierra, O. (2004) · Springer eBooks · doi:10.1007/978-94-007-1031-3_32 · Cited by 1
Evaluation of Antiphospholipid Antibodies
Greaves, M. (2013) · Wiley eBooks · doi:10.1002/9781118543467.ch20 · Cited by 1
Trombofilia venosa. Clasificaci?n, implicaciones cl?nicas y terap?uticas
Villamediana, R. L., Antn, M. P. S., Snchez, J. F., & Hernando, E. R. (2004) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(04)70214-3 · Cited by 1
Studies on cardiovascular risk factors in Systemic Lupus Erythematosus
Gustafsson, J. T. (2012) · Figshare · Cited by 1
Diagnóstico del síndrome antifosfolipídico: más actores, los mismos protagonistas
Ruiz‐Irastorza, G. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2009.11.027 · Cited by 1
Aspirin thromboprophylaxis of asymptomatic antiphospholipid-positive subjects
Galli, M. (2008) · Internal and Emergency Medicine · doi:10.1007/s11739-008-0203-6 · Cited by 1
“Lupus anticoagulants (LAC) consistently shows the highest strength of association with arterial and venous thrombotic complications in both adults and children [7].”
BackgroundSelf-citationRodríguez-Fernández, S., Ramírez, P. S., Garriga, G. E., & Segura, R. C. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)71823-5 · Cited by 1
Update on Thrombophilic Disorders
Thomas, R. (2003) · Laboratory Medicine · doi:10.1309/84ktm4626cn5vty4 · Cited by 1
Khamashta, M. A., Sciascia, S., & Bertolaccini, M. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-444-56378-1.00087-3 · Cited by 1
Genzen, J. R., & Miller, J. L. (2005) · American Journal of Clinical Pathology · doi:10.1309/7ryu-n5dr-k4wc-h3pm · Cited by 1
Serological Biomarkers in Systemic Lupus Erythematosus
Chan, M. T.-L. (2013) · The University of Bath Online Publications Store (The University of Bath)
β2-glycoprotein I and Anti-β2-glycoprotein I Antibodies
Yasuda, S., Atsumi, T., & Koike, T. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_25
Antiphospholipıd Syndrome and Venous Thrombosis
Okuyan, E. (2012) · InTech eBooks · doi:10.5772/27128
Antiphospholipid syndrome in patient with portal venous thrombosis: case report.
Damjanovska, L., & Rajcevski, R. (2011) · Macedonian Journal of Medical Sciences (University of Skopje) · doi:10.3889/mjms.1857-5773.2011.0178
Bilaterale rezidivierende retinale Thrombose bei einem jungen Mann
Harder, J., Thürmel, K., Maier, M. M., et al. (2009) · Der Ophthalmologe · doi:10.1007/s00347-009-1951-z
Antiphospholipid Antibodies – Detection and Clinical Importance
Swadźba, J., & Kolodziejczyk, J. (2012) · InTech eBooks · doi:10.5772/30530
“Although sensitive and quantitative ELISA-based methods were developed to detect antiphospholipid antibodies, LA detected by coagulometric tests has been shown to be more associated with thrombosis (Galli et al., 2003).”
MethodChapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome
Ruiz‐Irastorza, G., & Khamashta, M. A. (2009) · Technical report · doi:10.1016/s1571-5078(08)00415-7
Chapter 17 Treatment of Late Pregnancy Complications in the Antiphospholipid Syndrome
Nassar, A. H., Uthman, I. W., & Khamashta, M. A. (2009) · Technical report · doi:10.1016/s1571-5078(08)00417-0
Venous and arterial thrombosis : associations and risk factors
Roshani, S. (2012) · Leiden Repository (Leiden University)
Chapter 4 Antiphospholipid Syndrome
Sodin‐Šemrl, S., Rozman, B., Iglič, A., & Kralj‐Iglič, V. (2008) · Elsevier eBooks · doi:10.1016/s1554-4516(08)00004-5
PHOSPHOLIPID AUTOANTIBODIES (NON-ANTICARDIOLIPIN)–ANTI-PROTHROMBIN ANTIBODIES
Galli, M. (2007) · Elsevier eBooks · doi:10.1016/b978-044452763-9/50097-4
Self-citationAtteintes pleuro-pulmonaires associées au lupus érythémateux
Borie, R., & Crestani, B. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-71447-4.50035-0
Determinación del anticoagulante lúpico: Experiencia de 4 años
Concepción, A. D., Almagro, P. C., & González, Y. Z. (2005) · Revista cubana de hematología, inmunología y hemoterapia
Caso 01/2006: insuficiência cardíaca progressiva em homem de 44 anos de idade
dos Santos, T. S. G., Macedo, A. V. S., Moffa, P. J., et al. (2006) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2006000200013
Inherited thrombophilia and early pregnancy
Middeldorp, S. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777851.015
More about cellular signaling by antiphospholipid antibodies
Lackner, K. J. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13119
science [hematology and coagulation]: Update on Thrombophilic Disorders
Thomas, R. (2003) · Laboratory Medicine · doi:10.1309/84kt-m462-6cn5-vty4
Circulation Cardiovascular Case Series
Beckman, J. A., & Loscalzo, J. (2010) · Circulation · doi:10.1161/circulationaha.110.989160
Zakrzepica żylna i tętnicza jako objaw zespołu antyfosfolipidowego
Lehmann-Kopydłowska, A., & Zawilska, K. (2013) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2013.07.262
Autoimmune Diseases Promoting Coronary Disease in Women
Kazelián, L. R. (2013) · doi:10.7775/ajc.81.4.2890
Physiopathologie du syndrome des antiphospholipides
Pasquali, J.-L. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.09.007
Antiphospholipid Testing and Outcome—Reply
Ruiz‐Irastorza, G., Egurbide, M.-V., & Aguirre, C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.15.1701-c
Tromboembolia pulmonar e infartos cerebrales múltiples en una mujer de 36 años
Gómez‐Junyent, J., Martínez, N. R., & Carol, M. T. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.05.021
Éruption cutanée atypique au cours d’un syndrome des antiphospholipides
Gelot, P., Maillard, H., Ybarlucea, L. R. D., et al. (2012) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2012.01.019
Genomics and targeting antithrombotic therapy in antiphospholipid syndrome
Greaves, M. (2006) · Blood · doi:10.1182/blood-2005-11-4731
Syndrome des antiphospholipides: diagnostic biologique et physiopathologie
Darnige, L. (2006) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(06)80046-8
Le syndrome des antiphospholipides : actualités diagnostiques
Sanmarco, M. (2005) · Revue du Rhumatisme · doi:10.1016/j.rhum.2004.12.002
Antiphospholipid antibodies in acute cardiac attacks
Alajlan, S. (2013) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp12.110
“APLs had been associated to patients with arterial thrombosis including early coronary artery and cerebrovascular thrombosis (Galli et al., 2003).”
BackgroundAntiphospholipid antibodies in venous thromboembolism patients younger than 50 years old.
Halvani, A., Owlia, M. B., & Mehrpour, G. (2010) · Tanaffos: Journal of Respiratory Disease, Thoracic Surgery, Intensive Care and Tuberculosis
Determinants of adverse events during oral anticoagulant treatment
Lind, M. M. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Ivana, P. (2014) · Obstetrics & Gynecology International Journal · doi:10.15406/ogij.2014.01.00004
Antiphospholipid syndrome * Síndrome antifosfolípide *
Santamaría, J. R., Badziak, D., de Barros, M. F., Mandelli, F. L., Cavalin, L. C., & Sato, M. S. (2005)
Aryurachai, K., Angchaisuksiri, P., Atichartakarn, V., et al. (2005) · Journal of Hematology and Transfusion Medicine (วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต)
Stojanovich, L., Marković, O., Marisavljevic, D., Elezović, I. V., Ilijevski, N. S., & Stanisavljević, N. (2016)
Clinical Studies Examining Thrombosis Related to Autoimmune Antiphospholipid Antibodies
Bertolaccini, M. L., & Khamashta, M. A. (2010) · The Open Autoimmunity Journal
Manifestations neurologiques centrales du syndrome des anticorps antiphospholipides
Yelnik, C., Lambert, M., & HACHULLA, E. (2015) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2015.10.010
Task Force Report on “Non-criteria” Antiphospholipid Antibody Tests
Bertolaccini, M. L., Amengual, O., Atsumi, T., Binder, W. L., Kutteh, W. H., de Laat, B., Forastiero, R. R., Lambert, M., Matsubayashi, H., Murthy, V. L., et al. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3194-7_8
Tincani, A., Casu, C., Cartella, S., ZIGLIOLI, T., & Cattaneo, R. (2010)
The patient at risk from thrombosis and bleeding disorders
Greer, S. N. A. I. (2008) · CRC Press eBooks · doi:10.3109/9780203092200-14
Eular On-line Course on Rheumatic Diseases - module n°19
Khamashta, M. A., Bertolaccini, M. L., & Østensen, M. (2008)
Hypercoagulable Conditions Leading to Limb Ischemia
Jayaraj, A., Wysokiński, W. E., & McBane, R. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-31991-9_25
Prognosis in Antiphospholipid Syndrome
Serrano, R. M., Pons‐Estel, G., Espinosa, G., & Cervera, R. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00019-3
Treatment of Pregnancy Complications in Antiphospholipid Syndrome
Nassar, A. H., Uthman, I. W., Eid, J., & Khamashta, M. A. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00018-1
Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome
Amengual, O., Bertolaccini, M. L., & Atsumi, T. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00004-1
Standardization of antiphospholipid antibodies ELISA
Motoki, Y., Nojima, J., Yoshida, M., et al. (2016) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.27.644
Patnaik, M. M., Wudhikarn, K., Shroff, M. M., Killeen, A. A., Reding, M. T., & Kasthuri, R. S. (2008) · Blood · doi:10.1182/blood.v112.11.5343.5343
Diagnose des Antiphospholipid-Syndrom beim antikoagulierten Patient: Was gibt es zu beachten?
Mohren, M., Daikeler, T. D., Engel, A., Günaydın, İ., & Koetter, I. (2004) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-004-0593-4
“Der positive Nachweis eines LA scheint im Gegensatz zum Nachweis von ACL-AK mit einem erhöhten Risiko für Thromboembolien einherzugehen, was am ehesten dadurch bedingt ist, dass LA-spezifischere Antiphospholipid-Antikörper sind, während ACL-AK den sensitiveren Parameter für die Diagnose darstellen [5, 8, 11, 16].”
BackgroundGalambosi, P. J. (2017) · Työväentutkimus Vuosikirja
Idiopathic Osteonecrosis and Atypical Femoral Fracture in Systemic Lupus Erythematosus
Kuroda, T., & Sato, H. (2017) · Lupus · doi:10.5772/intechopen.68143
“In SLE, as is the case for antiphospholipid syndrome (APS), about 30–40% of patients have detectable antiphospholipid antibodies [36] and a positive lupus anticoagulant test and anticardiolipin antibody are detected in approximately 10–30% and 20–40% of patients, respectively.”
BackgroundTraitement anticoagulant au cours de la grossesse
Chauleur, C., & Barjat, T. R. (2017) · HAL · doi:10.1016/s0246-0335(17)73350-9
Síndrome de anticuerpos antifosfolípidos
Francès, C., & Chasset, F. (2018) · EMC - Dermatología · doi:10.1016/s1761-2896(18)92423-4
Das Antiphospholipid-Syndrom – Eine interdisziplinäre Herausforderung
Madlener, K. (2018) · Aktuelle Rheumatologie · doi:10.1055/a-0803-5179
“[24] Galli M, Luciani D, Bertolini G et al.”
BackgroundA swollen leg and cerebral infarctions in a 49-year-old woman
Raharja, A., Chng, C. C., & Timmis, A. (2018) · British Journal of Hospital Medicine · doi:10.12968/hmed.2018.79.12.714
Gutiérrez, L. R., & Gómez, A. P. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70565-1
Epidemiology of venous thromboembolism with focus on risk markers
Johansson, M. (2019) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Management of Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus
Yelovich, M., & Legault, K. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00126-w
Livedo Reticularis Associated with Ulceration
El-Darouti, M. A., & Al-Ali, F. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-21855-3_9
Epidemiological Profile of Thrombophilia in Marrakech (Morocco): About 200 Cases
Karrati, I., Mouhib, H., Yahyaoui, H., et al. (2019) · American Journal of Laboratory Medicine · doi:10.11648/j.ajlm.20190405.11
Quelles sont les particularités thérapeutiques au cours du syndrome des antiphospholipides ?
Benhamou, Y., Delluc, A., Am, F., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.017
Pulmonary involvement in antiphospholipid syndrome
Barratt, S. L., Pauling, J. D., & Chaudhuri, N. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10014419
Erkan, D., & Lockshin, M. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7234-3691-1.00074-x
Erkan, D., Salmon, J. E., & Lockshin, M. D. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00082-7
Lupus érythémateux disséminé et syndrome des anticorps anti-phospholipides
Adoué, D. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-74832-5.00040-3
Point-of-Care Testing in Hypercoagulable Conditions Managed With Warfarin
Faber, N. N., Bulmer, S. C., Gandhi, M. A., et al. (2020) · Point of Care The Journal of Near-Patient Testing & Technology · doi:10.1097/poc.0000000000000215
“To add to this, LA is a stronger risk factor for thrombosis than the other aPLs.(19) Further study is needed to determine the accuracy and safety of POCT devices in the LA-positive population.”
BackgroundUludağ, Ö., Yalçınkaya, Y., Gül, A., İnanç, M., Öçal, L., & Artım-Esen, B. (2020) · Ulusal Romatoloji Dergisi · doi:10.4274/raed.galenos.2020.30974
“Özellikle LA pozitifliği ile tromboz gelişimi arasında güçlü bir ilişki olduğu gösterilmiştir.[7,8] Üçlü aFL (LA, aKL ve aβ2GPI) pozitifliği ise trombotik riski en yüksek antikor profili olarak tanımlanmıştır.”
Lupus anticoagulants and the risk of a first episode of deep venous thrombosis
Root, P., & Isman, T. L. (2005)
Metadata
- Authors
- Galli, M., Luciani, D., Bertolini, G., & Barbui, T.
- Affiliations
- From the Division of Hematology, Ospedali Riuniti, Bergamo, Italy; and Laboratory of Clinical Epidemiology, Mario Negri Institute, Ranica (Bergamo), Italy.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-03-01
- Volume
- 101
- Issue
- 5
- Pages
- 1827-1832
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2044043417
- Cited by
- 972
- References
- 66
- Citations by year
- 2026: 23 · 2025: 22 · 2024: 32 · 2023: 28 · 2022: 34 · 2021: 40 · 2020: 37 · 2019: 39 · 2018: 30 · 2017: 41 · 2016: 57 · 2015: 36 · 2014: 40 · 2013: 41 · 2012: 50
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Keywords
- lupus anticoagulant, anticardiolipin antibodies, antiphospholipid syndrome, thrombosis, arterial thrombosis, venous thrombosis, thrombosis risk factors, systemic lupus erythematosus, antibody titers
- MeSH terms
- Arterial Occlusive Diseases, Autoantigens, Autoimmune Diseases, Cross-Sectional Studies, Glycoproteins, Humans, Myocardial Infarction, Prospective Studies, Prothrombin, Research Design, Risk Factors, Thrombosis, Confidence Intervals, Odds Ratio, Case-Control Studies, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Antibodies, Anticardiolipin, Thrombophilia, Venous Thrombosis, Stroke, beta 2-Glycoprotein I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
